The UK-based preclinical contractor announced its intention to come up with a fresh moniker in February, explaining that the decision to adopt a different sobriquet followed a “huge amount” of internal integration work.
In a press statement last night, CEO Brian Cass said choosing the alternative appellation marked a “hugely exciting time for our company” adding we “will be united with our customers in the knowledge that the research they conduct, and the products we help them develop, have the potential to enhance life.”
“Our new name and brand will reflect our integrated management structure and the broader product and service offerings of our combined organization.”
Huntingdon - which bought Harlan last May – claims to be the third largest provider of preclinical services to the pharmaceutical industry.
The UK-headquartered firm employs 3,800 people and has annual sales of approximately $500m (€447m).